HQY

Healthequity Inc

Add to Watchlist

Advanced Chart

92.460

-0.59(-0.634%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

94.010

Open

93.670

VWAP

92.94

Vol

607.16K

Mkt Cap

7.99B

Low

92.380

Amount

56.43M

EV/EBITDA(TTM)

21.72

Total Shares

87.01M

8.82B

EV/OCF(TTM)

25.99

P/S(TTM)

6.64

HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q4

FY2026Q3

FY2026Q2

334.03M

+7.12%

0.934

+35.32%

319.51M

+6.35%

0.901

+15.54%

320.69M

+6.92%

0.923

+7.3%

Estimates Revision

The market is revising Upward the revenue expectations for HealthEquity, Inc. (HQY) for FY2026, with the revenue forecasts being adjusted by 0.1% over the past three months. During the same period, the stock price has changed by -4.35%.

Revenue Estimates for FY2026

Revise Upward

+0.1%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+2.93%

In Past 3 Month

Stock Price

Go Down

-4.35%

In Past 3 Month

14 Analyst Rating

30.25% Upside

Wall Street analysts forecast HQY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HQY is 120.43 USD with a low forecast of 102.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

1 Hold

0 Sell

Strong Buy

30.25% Upside

Current: 92.460

Low

102.00

Averages

120.43

High

130.00

30.25% Upside

Current: 92.460

Low

102.00

Averages

120.43

High

130.00

Raymond James

C. Gregory Peters

Strong Buy

maintain

$115 -> $120

2025-07-08

Reason

Raymond James

C. Gregory Peters

Price Target

$115 -> $120

2025-07-08

maintain

Strong Buy

Reason

Raymond James analyst C. Gregory Peters raised the firm's price target on HealthEquity to $120 from $115 and keeps a Strong Buy rating on the shares. HealthEquity's management made considerable progress in Q1 on addressing the fraud activity that plagued the company in the last three quarters, the analyst tells investors in a research note. The firm expects HealthEquity to deliver double digit free cash flow and earnings growth with additional margin expansion through fiscal 2028.

Deutsche Bank

George Hill

Buy

maintain

$98 -> $115

2025-06-05

Reason

Deutsche Bank

George Hill

Price Target

$98 -> $115

2025-06-05

maintain

Buy

Reason

Deutsche Bank analyst George Hill raised the firm's price target on HealthEquity to $115 from $98 and keeps a Buy rating on the shares.

Barrington

Outperform

maintain

$112 -> $125

2025-06-05

Reason

Barrington

Price Target

$112 -> $125

2025-06-05

maintain

Outperform

Reason

Barrington raised the firm's price target on HealthEquity to $125 from $112 and keeps an Outperform rating on the shares. The company's Q1 topped expectations and its fiscal 2026 guidance was raised, the analyst tells investors in a research note. The firm says that with a "strong and industry-leading" health savings account business, combined with a higher effective yield on cash, HealthEquity's operating and financial performance should continue to improve on a consolidated basis going forward.

Citizens JMP

Outperform

maintain

$110 -> $117

2025-06-04

Reason

Citizens JMP

Price Target

$110 -> $117

2025-06-04

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on HealthEquity to $117 from $110 and keeps an Outperform rating on the shares. HealthEquity reported Q1 results and increased the lower end of its fiscal 2026 revenue outlook and adjusted EPS view, the analyst tells investors in a research note. The firm believes that enhanced security measures will prove successful at neutralizing fraud.

BofA

Buy

maintain

$110 -> $125

2025-06-04

Reason

BofA

Price Target

$110 -> $125

2025-06-04

maintain

Buy

Reason

BofA raised the firm's price target on HealthEquity to $125 from $110 and keeps a Buy rating on the shares following "a strong quarter" with revenue and EPS significantly exceeding Street expectations. The biggest focus heading into the quarter was the trajectory of fraud costs, but the firm notes that HealthEquity experienced less fraud costs each month in Q1 and believes the company has put in place "the right guardrails to slow this activity on the platform." The firm's higher multiple reflects greater confidence fraud costs are under control and underwrites some benefits from legislation not embedded in its estimates, the analyst tells investors.

RBC Capital

Outperform

maintain

$112 -> $117

2025-06-04

Reason

RBC Capital

Price Target

$112 -> $117

2025-06-04

maintain

Outperform

Reason

RBC Capital raised the firm's price target on HealthEquity to $117 from $112 and keeps an Outperform rating on the shares. The company delivered strong Q1 results that were well above the Street estimates, and more importantly, put the major investor concern of continued elevated fraud expense to rest, calling out declines in fraud activity while showcasing that its new controls are working, the analyst tells investors in a research note. With regulatory tailwinds from the pending reconciliation bill, the earnings call was also highly positive, RBC added.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Healthequity Inc (HQY.O) is 24.06, compared to its 5-year average forward P/E of 36.33. For a more detailed relative valuation and DCF analysis to assess Healthequity Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

36.33

Current PE

24.06

Overvalued PE

47.99

Undervalued PE

24.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

19.94

Current EV/EBITDA

15.71

Overvalued EV/EBITDA

24.35

Undervalued EV/EBITDA

15.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

6.19

Current PS

6.06

Overvalued PS

7.22

Undervalued PS

5.16